Biotron（BIT）株式概要バイオテクノロジー企業であるバイオトロン・リミテッドは、オーストラリアで様々なウイルス性疾患を治療するための低分子製品の開発と商業化に従事している。 詳細BIT ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析意味のある時価総額がありません ( A$8M )過去1年間で株主の希薄化は大幅に進んだ 収益が 100 万ドル未満 ( A$-868 )Australian市場と比較して、過去 3 か月間の株価の変動が非常に大きいすべてのリスクチェックを見るBIT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueAU$Current PriceAU$0.002該当なし内在価値ディスカウントEst. Revenue$PastFuture-4m3m2016201920222025202620282031Revenue AU$0.9Earnings AU$0.2AdvancedSet Fair ValueView all narrativesBiotron Limited 競合他社PatrysSymbol: ASX:PABMarket cap: AU$24.7mHeximaSymbol: ASX:HXLMarket cap: AU$2.2mNeuroScientific BiopharmaceuticalsSymbol: ASX:NSBMarket cap: AU$31.3mTissue RepairSymbol: ASX:TRPMarket cap: AU$7.3m価格と性能株価の高値、安値、推移の概要Biotron過去の株価現在の株価AU$0.00252週高値AU$0.00552週安値AU$0.002ベータ-0.551ヶ月の変化-33.33%3ヶ月変化-33.33%1年変化-20.00%3年間の変化-92.59%5年間の変化-96.08%IPOからの変化-97.66%最新ニュースBoard Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). MD & Executive Director Michelle Miller is the most experienced director on the board, commencing their role in 2002. Independent & Non-Executive Chairman Paul Kasian was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • May 01Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent & Non-Executive Director Paul Kasian was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • Mar 30Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026Biotron Limited announced the appointment of Graeme Wald as Non-Executive Director, effective March 30, 2026. Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd. and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.お知らせ • Jan 30Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 215,286,751 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 292,666,664 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights OfferingBoard Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michael Medway was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 02Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,664 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,669 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing最新情報をもっと見るRecent updatesBoard Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). MD & Executive Director Michelle Miller is the most experienced director on the board, commencing their role in 2002. Independent & Non-Executive Chairman Paul Kasian was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • May 01Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent & Non-Executive Director Paul Kasian was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • Mar 30Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026Biotron Limited announced the appointment of Graeme Wald as Non-Executive Director, effective March 30, 2026. Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd. and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.お知らせ • Jan 30Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 215,286,751 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 292,666,664 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights OfferingBoard Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michael Medway was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 02Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,664 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,669 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 15Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,876 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,457 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Sep 29Biotron Limited, Annual General Meeting, Nov 17, 2025Biotron Limited, Annual General Meeting, Nov 17, 2025.お知らせ • Feb 28+ 1 more updateBiotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 652,382,667 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 250,000,000 Price\Range: AUD 0.003 Transaction Features: Rights Offeringお知らせ • Feb 21Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 270,714,829 Price\Range: AUD 0.01New Risk • Feb 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Market cap is less than US$10m (AU$9.02m market cap, or US$5.67m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m).Board Change • Feb 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Independent & Non-Executive Director Rob Thomas was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Dec 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Independent & Non-Executive Director Rob Thomas was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 28Biotron Limited Announces Board RetirementDr. Susan Pond and Professor Stephen Locarnini, Non-Executive Directors, have retired as Directors of Biotron Limited (Biotron) as of 28 November 2024. Dr. Pond has been a Director since 7 March 2012 and Professor Locarnini since 23 October 2018.お知らせ • Oct 22Biotron Limited, Annual General Meeting, Nov 28, 2024Biotron Limited, Annual General Meeting, Nov 28, 2024. Location: level 38 tower 3 international tower, sydney 300, barangaroo ave sydney, nsw 2000, sydney AustraliaNew Risk • Sep 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m). Market cap is less than US$100m (AU$20.8m market cap, or US$14.0m).New Risk • Sep 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Market cap is less than US$10m (AU$14.4m market cap, or US$9.63m). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m).New Risk • Jun 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.7m free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m). Market cap is less than US$100m (AU$33.4m market cap, or US$22.2m).お知らせ • Oct 20Biotron Limited, Annual General Meeting, Nov 22, 2023Biotron Limited, Annual General Meeting, Nov 22, 2023, at 11:00 AUS Eastern Standard Time. Location: Level 3, 60 Carrington Street, Sydney, NSW, 2000 Sydney Australia Agenda: To receive and consider the Company's annual financial report, the directors' report and the auditors' report for the year ended 30 June 2023; to consider the That Dr. Susan M. Pond be and is hereby re-elected as a Director; to consider the That the Remuneration Report for the year ended 30 June 2023 be and is hereby adopted; to consider the Re-election of Dr. Susan M. Pond as a Director; and to consider other matters.New Risk • Jul 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (AU$3.0m revenue, or US$2.1m). Market cap is less than US$100m (AU$31.6m market cap, or US$21.7m).Board Change • Nov 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.株主還元BITAU BiotechsAU 市場7D-33.3%0.6%0.08%1Y-20.0%-55.8%3.1%株主還元を見る業界別リターン: BIT過去 1 年間で-55.8 % の収益を上げたAustralian Biotechs業界を上回りました。リターン対市場: BITは、過去 1 年間で3.1 % のリターンを上げたAustralian市場を下回りました。価格変動Is BIT's price volatile compared to industry and market?BIT volatilityBIT Average Weekly Movement28.5%Biotechs Industry Average Movement11.0%Market Average Movement10.5%10% most volatile stocks in AU Market17.5%10% least volatile stocks in AU Market4.3%安定した株価: BITの株価は、 Australian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: BITの weekly volatility ( 29% ) は過去 1 年間安定していますが、依然としてAustralianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1999n/aMichelle Millerwww.biotron.com.auバイオテクノロジー企業であるバイオトロン・リミテッドは、オーストラリアで様々なウイルス性疾患を治療する低分子製品の開発・商業化に従事している。同社の主力抗ウイルス薬はBIT225で、SARS-CoV-2、HIV-1、C型肝炎ウイルス感染の治療薬として第II相臨床試験中である。バイオトロン・リミテッドは1999年に設立され、オーストラリアのシドニーに本社を置いている。もっと見るBiotron Limited 基礎のまとめBiotron の収益と売上を時価総額と比較するとどうか。BIT 基礎統計学時価総額AU$8.11m収益（TTM）-AU$1.94m売上高(TTM)n/a-9,338xP/Sレシオ-4.2xPER（株価収益率BIT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BIT 損益計算書（TTM）収益-AU$868.00売上原価AU$0売上総利益-AU$868.00その他の費用AU$1.94m収益-AU$1.94m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.00072グロス・マージン100.00%純利益率223,061.06%有利子負債／自己資本比率0%BIT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 18:22終値2026/05/20 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biotron Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). MD & Executive Director Michelle Miller is the most experienced director on the board, commencing their role in 2002. Independent & Non-Executive Chairman Paul Kasian was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • May 01Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent & Non-Executive Director Paul Kasian was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • Mar 30Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026Biotron Limited announced the appointment of Graeme Wald as Non-Executive Director, effective March 30, 2026. Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd. and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.
お知らせ • Jan 30Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 215,286,751 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 292,666,664 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights Offering
Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michael Medway was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 02Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,664 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,669 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Board Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). MD & Executive Director Michelle Miller is the most experienced director on the board, commencing their role in 2002. Independent & Non-Executive Chairman Paul Kasian was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • May 01Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent & Non-Executive Director Paul Kasian was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • Mar 30Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026Biotron Limited announced the appointment of Graeme Wald as Non-Executive Director, effective March 30, 2026. Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd. and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.
お知らせ • Jan 30Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 215,286,751 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 292,666,664 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights Offering
Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michael Medway was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 02Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,664 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,669 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 15Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,876 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,457 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Sep 29Biotron Limited, Annual General Meeting, Nov 17, 2025Biotron Limited, Annual General Meeting, Nov 17, 2025.
お知らせ • Feb 28+ 1 more updateBiotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 652,382,667 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 250,000,000 Price\Range: AUD 0.003 Transaction Features: Rights Offering
お知らせ • Feb 21Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 270,714,829 Price\Range: AUD 0.01
New Risk • Feb 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Market cap is less than US$10m (AU$9.02m market cap, or US$5.67m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m).
Board Change • Feb 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Independent & Non-Executive Director Rob Thomas was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Dec 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Independent & Non-Executive Director Rob Thomas was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 28Biotron Limited Announces Board RetirementDr. Susan Pond and Professor Stephen Locarnini, Non-Executive Directors, have retired as Directors of Biotron Limited (Biotron) as of 28 November 2024. Dr. Pond has been a Director since 7 March 2012 and Professor Locarnini since 23 October 2018.
お知らせ • Oct 22Biotron Limited, Annual General Meeting, Nov 28, 2024Biotron Limited, Annual General Meeting, Nov 28, 2024. Location: level 38 tower 3 international tower, sydney 300, barangaroo ave sydney, nsw 2000, sydney Australia
New Risk • Sep 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m). Market cap is less than US$100m (AU$20.8m market cap, or US$14.0m).
New Risk • Sep 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Market cap is less than US$10m (AU$14.4m market cap, or US$9.63m). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m).
New Risk • Jun 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.7m free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m). Market cap is less than US$100m (AU$33.4m market cap, or US$22.2m).
お知らせ • Oct 20Biotron Limited, Annual General Meeting, Nov 22, 2023Biotron Limited, Annual General Meeting, Nov 22, 2023, at 11:00 AUS Eastern Standard Time. Location: Level 3, 60 Carrington Street, Sydney, NSW, 2000 Sydney Australia Agenda: To receive and consider the Company's annual financial report, the directors' report and the auditors' report for the year ended 30 June 2023; to consider the That Dr. Susan M. Pond be and is hereby re-elected as a Director; to consider the That the Remuneration Report for the year ended 30 June 2023 be and is hereby adopted; to consider the Re-election of Dr. Susan M. Pond as a Director; and to consider other matters.
New Risk • Jul 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (AU$3.0m revenue, or US$2.1m). Market cap is less than US$100m (AU$31.6m market cap, or US$21.7m).
Board Change • Nov 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
